eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
2/2020
vol. 45
 
Share:
Share:
abstract:
Original paper

Avidity of anti-phospholipid antibodies in relation to their levels

Lenka Fialová
1
,
Oliver Kuchař
1
,
Milada Petráčková
1
,
Ivan Malbohan
1
,
Tomáš Zima
1

1.
Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
Cent Eur J Immunol 2020; 45 (2): 136-143
Online publish date: 2020/07/27
View full text Get citation
 
PlumX metrics:
Introduction
The heterogeneity of anti-phospholipid antibodies can be manifested not only in different antigenic specificities, but also in their avidities. The aim of the study was to investigate the relationship between anti-cardiolipin antibody (aCL) IgG avidities and levels within the range of their titres, from very low to high ones.

Material and methods
We analyzed 78 serum samples from 60 patients by ELISA with chaotropic agents, using urea concentration of 6 and 8 mol/l and single diluted serum samples. The changes of aCL levels and avidities were explored during a long-term follow-up in 14 patients.

Results
The avidities of aCLs did not differ in the groups of patients classified according to aCL levels. The higher avidity antibodies predominated in our patients and the fluctuation of avidities in the longitudinal follow-up did not show significant differences. No relationship between aCL levels and their avidities was found.

Conclusions
aCL avidities seem to have no relationship with aCL levels and high-avidity aCLs; the potentially deleterious effects might be present also in patients with low and extremely low aCL levels. Avidity of aCLs

keywords:

anti-cardiolipin antibodies, anti-phospholipid antibodies, avidity, ELISA, chaotropic agents, urea, thrombosis, systemic lupus erythematosus

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.